July 2019 pharmaceutical M&A round-up

2 August 2019

Arguably the biggest news of the month from an M&A perspective was the merger of Netherlands-incorporated Mylan (Nasdaq: MYL) and the off-patent business of New York-based pharma giant Pfizer (NYSE: PFE), creating a generics powerhouse.

But it was by no means the only noteworthy activity, with other big names also announcing acquisitions, including Gilead Sciences (Nasdaq: GILD), AbbVie (Nadaq: ABBV), Boehringer Ingelheim and Roche's (ROG: SIX) Genentech unit.

Our table below details the month's major activity:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK